

AD \_\_\_\_\_

GRANT NUMBER DAMD17-94-J-4131

TITLE: Vasopressin and Breast Cancer

PRINCIPAL INVESTIGATOR: Michael J. Fay, Ph.D.

CONTRACTING ORGANIZATION: Dartmouth College  
Hanover, New Hampshire 03755-3580

REPORT DATE: August 1997

TYPE OF REPORT: Final

PREPARED FOR: Commander  
U.S. Army Medical Research and Materiel Command  
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 2

19980209 037

# REPORT DOCUMENTATION PAGE

Form Approved

OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 1997		3. REPORT TYPE AND DATES COVERED Final (1 Sep 94 - 31 Aug 97)	
4. TITLE AND SUBTITLE Vasopressin and Breast Cancer				5. FUNDING NUMBERS DAMD17-94-J-4131	
6. AUTHOR(S) Michael J. Fay, Ph.D.					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Dartmouth College Hanover, New Hampshire 03755-3580				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, MD 21702-5012				10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200)  Previously we demonstrated expression of vasopressin and oxytocin gene-related products in breast cancer, but not benign fibrocystic breast disease, using the technique of immunohistochemistry. In vitro and in vivo studies suggest that both of these hormones have growth regulatory effects on breast cancer cells. Therefore, these hormones may represent autocrine/paracrine and/or endocrine factors for breast cancer. However, the receptors through which these hormones act and the effector mechanisms involved with cancer cell growth are not known. Using RT-PCR we demonstrated the expression of mRNA for the 4 known vasopressin receptors, including the novel VACM receptor, and the oxytocin receptor. During this last year we cloned VACM from cancer cells (NCI-H146 and MCF7), using the technique of 5' and 3'-RACE. The isolated clones contains an open reading frame of 2,343 nucleotides and encode a protein of 781 amino acids. Obtaining the cDNA for VACM will aid in determining the role of this receptor in breast cancer pathophysiology. In addition we have demonstrated vasopressin-induced calcium mobilization in breast cancer cells, and preliminary results indicate vasopressin-induced activation of MAPK. The studies suggest that vasopressin may stimulate cancer cell growth through VACM, V <sub>1a</sub> , or V <sub>1b</sub> vasopressin receptors by activating the MAP kinase cascade.					
14. SUBJECT TERMS Humans, Anatomical Samples, Vasopressin, Vasopressin-Receptor, Growth Factor, Cell-Surface Antigen, Early Detection, Treatment, Breast Cancer				15. NUMBER OF PAGES 25	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited		

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

\_\_\_\_ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

MSF Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

\_\_\_\_ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

MSF For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

\_\_\_\_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

\_\_\_\_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

\_\_\_\_ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Michael J. J. 9/25/97  
PI - Signature Date

#### **(4) TABLE OF CONTENTS**

ITEM	PAGE NUMBER
(1) FRONT COVER	1
(2) STANDARD FORM (SF) 298	2
(3) FOREWORD	3
(4) TABLE OF CONTENTS	4
(5) INTRODUCTION	5 - 7
(6) BODY	7 - 11
(7) CONCLUSIONS	11-13
(8) REFERENCES	13 - 16
(9) APPENDICES	17 - 25

## (5) INTRODUCTION

Vasopressin and oxytocin are nine amino acid hormones (nonapeptides) which are produced by distinct neurons in the paraventricular and supraoptic nuclei in the hypothalamus of the brain. The major physiological roles for vasopressin (antidiuretic hormone) include antidiuresis, vasopressor effects, and modulation of adrenocorticotrophic hormone (ACTH) release from the anterior pituitary. The physiological roles for oxytocin include contraction of smooth muscle cells which result in lactation, and the uterine contractions which are important for parturition. These diverse actions of vasopressin and oxytocin are mediated by a number of specific cell-surface receptors which will be discussed below. Like many other peptide hormones, vasopressin and oxytocin are produced as prohormones, which are packaged into neurosecretory vesicles. In these vesicles the prohormones are acted on by processing enzymes which result in the generation of distinct peptide products. Processing of the vasopressin precursor results in the generation of three distinct gene-products (vasopressin, vasopressin-associated neurophysin, and vasopressin-associated glycopeptide) (North, 1987). Processing of the oxytocin precursor results in the generation of the active hormone and an oxytocin-associated neurophysin (North, 1987). These neurosecretory vesicles, containing the vasopressin and oxytocin gene-related products, come to reside in the axonal terminals of neurons which are located in the posterior pituitary. Physiological stimulation causes an action potential in these neurons which results in the release of active hormone and distinct gene-products into the circulation. In addition to the production of these hormones within the CNS, a number of studies suggest that peptide hormones, like oxytocin and vasopressin, can be produced by a number of peripheral tissues. It is thought that this peripheral production of oxytocin and vasopressin may represent an autocrine/paracrine role for these peptides in addition to their well established endocrine roles (Wathes and Swann, 1982; Ivell and Richter, 1984; Nicholson et al., 1984; Nussey et al., 1984; Wathes, 1984; Ivell et al., 1985; Schwams et al., 1985).

It has been known for some time that certain cancers, such as small-cell lung carcinoma, can ectopically produce neuropeptide hormones like oxytocin and vasopressin (Sausville et al., 1985; North, 1991; North et al., 1995). Research performed in this laboratory, using the technique of immunohistochemistry and archival breast cancer and fibrocystic breast disease specimens, indicates that expression of vasopressin and oxytocin gene-related products is a common feature of breast cancer (North et al., 1995), but not benign fibrocystic breast disease (Fay et al., submitted 1997). The ability of breast cancer cells to process peptide prohormones and generate active hormone, like vasopressin and oxytocin, is supported by the recent finding that both breast cancer cell lines and biopsy specimens express prohormone processing enzymes (Cheng et al., 1997). In many cases this ectopic production and secretion of hormone can result in paraneoplastic syndromes which are characterized by clinical symptoms resulting from hormone excess (Sorenson et al., 1995). In further support of a connection between vasopressin and breast cancer, there are two published clinical case reports of breast cancer patients presenting with the syndrome of inappropriate antidiuretic hormone secretion (SIADH) (Gupta et al., 1986; Howard et al., 1993). Collectively, these findings suggest that neuropeptide expression/secretion by breast cancer cells may represent a potential diagnostic biomarker

for this cancer, and suggests a possible role of neuropeptides as cancer cell autocrine/paracrine factors. In addition, the expression of unprocessed or modified neuropeptide gene-products on the cell surface of the cancer cells might prove to be a potential therapeutic target as in small-cell lung cancer (North et al., 1989; Rosenbaum et al., 1990; North and Yu, 1993; see initial progress report for cell surface vasopressin-like immunoreactivity in MCF7 breast cancer cells).

The diverse physiological actions of vasopressin and oxytocin are carried out by the binding of hormone to cell surface receptors located in specific target tissues. In the case of vasopressin, 4 cell surface receptors have been identified and cloned. The antidiuretic actions of vasopressin occur through activation of renal  $V_2$  type receptors (Birnbaumer et al., 1992). The  $V_2$  type vasopressin receptor belongs to the 7-transmembrane superfamily of G-protein coupled receptors, and activation results in an increase in adenylate cyclase activity, increases in cAMP, and activation of protein kinase A. The cloned  $V_{1a}$  and  $V_{1b}/V_3$  vasopressin receptors are also 7-transmembrane G-protein coupled receptors (Keyzer et al., 1994; Hirasawa et al., 1994; Thibonnier et al., 1994). The  $V_{1a}$  vasopressin receptor is located in vascular smooth muscle and is responsible for the vasopressor effects of vasopressin, while the  $V_{1b}/V_3$  vasopressin receptor is located in the anterior pituitary and is responsible for modulating the release of adrenocorticotrophic hormone (ACTH). Both receptor types couple to phospholipases, and receptor activation results in the generation of inositol phosphates, rises in intracellular calcium, and activation of protein kinase C. In addition to these vasopressin receptors, a novel vasopressin receptor was recently cloned, and was named the vasopressin-activated calcium mobilizing receptor or VACM (Burnatowska-Hledin et al., 1995). This receptor is unique in that hydrophobicity plots indicate that it does not belong to the 7-transmembrane G-protein coupled receptor superfamily. In addition, upon vasopressin binding/interaction this receptor increases intracellular calcium by an as yet undefined mechanism. The cloned human oxytocin receptor is also a member of the 7-transmembrane G-protein coupled receptor superfamily, and in the physiological setting activates signal transduction pathways similar to the  $V_1$  vasopressin receptors (Kimura et al., 1992).

For neuropeptides like vasopressin and oxytocin to serve as autocrine/paracrine and/or endocrine growth regulatory factors for breast cancer cells, the expression of vasopressin receptor subtypes and functionality of these receptors must be determined. As presented in last years progress report and in the enclosed abstract for the DODera of Hope meeting, I have demonstrated the expression of mRNAs for vasopressin receptors and for the oxytocin receptor in a number of cultured breast cancer cell lines. In addition, I have also demonstrated vasopressin-induced calcium mobilization in cultured breast cancer cell lines. Collectively these results suggest that vasopressin, acting through  $V_1$  or the recently identified VACM receptor, influences breast cancer cells by raising intracellular-free calcium. Such findings are consistent with the research of Taylor et al (1990), who found that vasopressin increased levels of total inositol phosphates in cultured breast cancer cells. These findings indicate that breast cancer cells express a number of neuropeptide receptor subtypes, and indicate vasopressin receptor functionality. I was unable to demonstrate oxytocin-induced calcium mobilization, despite the expression of mRNA for this receptor in the cell lines examined. Recently Cassoni et al.

(1997), demonstrated that oxytocin induced the accumulation of cAMP, but not calcium mobilization, in the MDA-MB-231 breast cancer cell line. This rise in cAMP was also correlated with a growth-inhibitory effect of oxytocin (Cassoni et al., 1994), these findings are in contrast to the growth promoting influences found by Taylor et al. (1990) for oxytocin, which were correlated with increases in total inositol phosphates. The findings of Cassoni et al. (1997) corroborates the lack of oxytocin-induced calcium mobilization we observed in other breast cancer cell lines (Zr-75 and T47D), and implicates that oxytocin receptor coupling and signal transduction in breast cancer cells is regulated differently than in normal oxytocin target tissue. One possible explanation for the discrepancies in oxytocin receptor signal transduction in breast cancer cells may be coupling of the receptor to multiple G-proteins (Milligan, 1993), or cross talk between signal transduction pathways. I am in the process of preparing the oxytocin receptor RT-PCR data and oxytocin-induced lack of calcium mobilization data for publication.

Vasopressin has been shown to stimulate breast cancer cell growth both in vitro (Taylor et al., 1990), and in vivo (Chooi et al., 1994). However, the receptors and signal transduction mechanisms have not been elucidated. The RT-PCR results we have obtained suggest that vasopressin may be acting at several receptors to modulate cancer cell growth, and not just the V1a receptor as has been postulated by others (Chooi et al., 1994). The sequence of signal transduction events associated with vasopressin-induced breast cancer-growth are also unknown. Taylor et al (1990) correlated a rise in intracellular inositol phosphates with vasopressin-induced growth of breast cancer cells, and we have demonstrated increases in intracellular free calcium. These signal transduction events suggest activation of vasopressin V<sub>1</sub> receptors and/or activation of VACM receptors. In addition to the growth inhibition found with oxytocin-receptor activation (Cassoni et al., 1994), the expression of V2 receptors by cancer cells may represent a possible negative growth regulatory mechanism, since cAMP has been shown to inhibit the growth of breast cancer (Tagliaferri et al., 1988). One possible mechanism by which neuropeptides may influence cancer cell growth is by activating the mitogen-activated protein kinase (MAPK) cascade, a pathway common to growth promoting stimuli (Davis 1993; L'Allemain, 1994; Cobb and Goldsmith, 1995). In Physiological settings both oxytocin and vasopressin are capable of activating the MAP kinase cascade (Kribben et al., 1993; Ohmichi et al., 1995; Nohara et al., 1996), and preliminary findings by this laboratory support the idea that vasopressin may be stimulating MAPK phosphorylation in cultured breast cancer cells.

## **(6) BODY**

### **A. Immunohistochemical detection of vasopressin gene-related products in benign fibrocystic disease**

We have submitted our initial results on the immunohistochemical evaluation of vasopressin gene expression in benign fibrocystic disease to Endocrine Pathology for consideration for publication (see last years progress report for preprint of paper). This paper was deemed acceptable for publication pending revisions and some additional research. The reviewers for this journal wanted to see cases of acetone-fixed fibrocystic

disease stained for vasopressin gene-related products, in addition to the formaldehyde-fixed tissues we examined, since the original breast cancer work we published was performed using acetone-fixed breast cancer specimens (North et al., 1995). In addition, the reviewers wanted to see staining for vasopressin gene-related products performed on cancer biopsy specimens from patients who were initially diagnosed with benign fibrocystic disease. We have initiated the process of locating the archival tissue specimens, preparing slides from the blocks, and staining the tissue sections using our antibody to vasopressin-associated glycopeptide. We are in the process of performing dilution trials with the anti-vasopressin associated glycopeptide antibody, and confirming tissue pathology and staining with Dr. Vincent Memoli of Dartmouth Hitchcock Medical Center. When these immunohistochemical experiments are finished the paper will be revised and resubmitted to Endocrine Pathology. The continuing work on the immunohistochemical detection of vasopressin-gene related products in breast cancer and benign fibrocystic breast disease addresses technical objective 1 of the original grant application.

**B. Cloning of a novel calcium mobilizing vasopressin receptor from cancer cells (NCI-H146 small cell-lung cancer cells and MCF7 breast cancer cells).**

As mentioned in the last progress report I was able to demonstrate expression of mRNA for the novel vasopressin receptor, called VACM, in breast cancer cell lines using the technique of RT-PCR and primers designed against the rabbit VACM sequence. Since that time a human clone of VACM was published by a British research team (Byrd et al., 1997; Stankovic et al., 1997). In order to study the role of this receptor in cancer cells, a large laboratory effort was undertaken to obtain a cDNA clone for this receptor from human cancer cells. These studies address technical objective 3 of the original grant application. Initial efforts were focused on the small-cell lung carcinoma cell line NCI-H146, since we had obtained signal transduction results supporting the expression of functional VACM in this cell line. However, we have subsequently obtained the 5' and 3' RACE (rapid amplification of cDNA ends) products, covering the entire open reading frame of this gene, from the MCF-7 breast cancer cell line. The procedures used to isolate a cDNA clone of VACM from human cancer cells are as follows. Approximately 1 µg of total RNA was subjected to reverse transcription using the superscript II enzyme (Life Technologies), and the 138 primer (see below). The RACE PCR technique was performed using the primers listed below and Pfu polymerase (Stratagene). The conditions used were as follows: an initial denaturation step at 96 °C for 2.5 min; 35 cycles of 96 °C for 45 sec, 55 °C for 45 sec, and 72 °C for 8 min; followed by a final extension of 20 min. The generated products (~2.1 kb and 1.6 kb) were cloned into the pZERO-(Blunt) vector (Invitrogen). Sequencing of the generated clones was performed using an ABI/Prism automated sequencing system (Perkin Elmer). Sequence analysis was performed using Align/Megalign (DNASTar, Inc.), and Gene Inspector (Textco, Inc.) software programs, and protein motif analysis was performed using the Internet version of MotifFinder (Institute for Chemical Research, Kyoto University).



3'-PCR RACE primers for VACM:

1432(forward):        5' gaa-tgg-cta-aga-gaa-gtt-ggt-atg 3'  
138(reverse):        5' ttg-ttt-ttg-taa-ggt-aag-gca-gag 3'

5'-PCR RACE primers for VACM:

5' ATG (forward):    5' tcc-aag-tta-aag-aac-atg-gcg 3'  
2082 (reverse):      5' tct-tct-ctc-atc-ctt-tct-gta-gtg 3'

The isolated clone for NCI-H146 contains an open reading frame of 2,343 nucleotides and encodes a protein of a predicted size of 781 amino acids. Analysis programs failed to identify hydrophobicity regions of significance to classify them as transmembrane regions. Motifs identified included two protein kinase A phosphorylation domains (Thr 427 and Ser 731), 15 protein kinase C phosphorylation sites, a tyrosine phosphorylation site Tyr 207, two myristoylation sites contained by residues 180..185 and 664..669, and three N-glycosylation sites at Asn 145, Asn 289, and Asn 566. These findings are unpublished, and we are in the process of preparing the manuscript. The cDNA sequence for HVACM from human cancer cells has been submitted to the Genebank by us and has an assigned accession number of AF017061. A complete copy of the gene bank submission is included in the appendices of this progress report. Now that we have cloned VACM from a human cancer cell line, we have the molecular information needed to examine in detail the expression of this mRNA and protein, so that it's interactions with vasopressin and role in breast cancer cell biology can be fully examined.

### **C. Vasopressin-induced phosphorylation (activation) of mitogen-activated protein kinase (MAPK).**

In an effort to further examine the influence of vasopressin on activation of MAPK in MCF7 breast cancer cells I have devoted a considerable amount of time to the development of a fluorescent western-blot protocol which we have attempted to quantify using a recently purchased Molecular Dynamics Fluorimager. These studies address technical objective 3 of the original grant application. The materials and methods used for these experiments are as follows. MCF7 breast adenocarcinoma cells were obtained from the American Type Culture Collection (ATCC HTB22). The cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Sigma) supplemented with 10% fetal bovine serum (FBS; Hyclone) at 37 °C in an environment of 5% CO<sub>2</sub>. Every 2-3 days the cells either received fresh growth medium or were subcultured using 0.25% trypsin/0.02% EDTA. For experimental purposes, cells were trypsinized, counted using trypan blue and a hemocytometer, and 2 x 10<sup>6</sup> viable cells were seeded into 6-well plates (Costar) in 3 ml of DMEM containing 1% FBS. The cells were plated out in these reduced serum conditions to decrease MAPK activity (phosphorylation). These conditions did not appear

to influence cell attachment to the plates. On the day of experimentation, the media was aspirated and replaced with DMEM containing 0.5% FBS for 2 hours. This was done to eliminate possible endogenous autocrine/paracrine growth factors secreted by the cancer cells. The cells were then treated for 5 or 15 minutes with 1  $\mu$ M arginine vasopressin (AVP; Calbiochem). The working concentration of AVP was obtained by a 1:1,000 dilution of a 1 mM stock in 0.05 M glacial acetic acid. Controls for these experiments included a DMEM/0.05% FBS media control, and an acetic acid control (DMEM/0.05% FBS + 50  $\mu$ M glacial acetic acid). After AVP treatment (5 or 15 min) at 37 °C, experimental solutions were aspirated, and cells lysed in 100  $\mu$ l of boiling SDS sample buffer containing 62.5 mM Tris HCl (pH 6.8), 2% w/v SDS, 10% glycerol, 50 mM DTT, and 0.1% w/v bromophenol blue. The lysed cells were scraped into 1.5 ml eppendorf tubes, boiled for 5 min, and passed through a 26 gauge needle to reduce viscosity. A 20  $\mu$ l aliquot of each sample was electrophoresed at 75 volts for 3.5 hours using a 12% polyacrylamide separating gel. Controls samples consisting of 5  $\mu$ l of either non-phosphorylated p42 MAPK or dually phosphorylated p42 MAPK (New England Biolabs) were also evaluated. A prestained protein ladder (10  $\mu$ l) was also run on each gel as a means of determining relative protein mass (BioRAD). After electrophoresis, proteins were transferred to a PVDF-plus membrane (MSI) at 15 volts for 12 hours at 4 °C.

The membranes were then subjected to Western blotting using antibodies which recognize dually phosphorylated MAPK (activated MAPK), and MAPK regardless of phosphorylation status. Membranes were first blocked at room temperature for 3 hours using 3.5% fish skin gelatin (Sigma) in 10 ml of tris-buffered saline with 2% heat inactivated casein (Sigma). After blocking the membranes were exposed to primary antibody in 10 ml of TBS-tween overnight at 4 °C. The rabbit polyclonal anti-active MAPK antibody recognizes dually phosphorylated p42/p44 MAPK, and was used at a dilution of 1:5,000 (Promega). The rabbit polyclonal antibody which recognizes p42/p44 MAPK regardless of phosphorylation status was used at a concentration of 1:1,000 (New England Biolabs). The next day, primary antibody was decanted, membranes washed 3 x 5 minutes with TBS-tween, and exposed to alkaline-phosphate conjugated goat anti-rabbit (1:2,000) for 1 hour at room temperature. The membranes were then washed 3 x 5 min in TBS-tween, and exposed to 2 ml of ECL substrate (Amersham). The membranes were then wrapped in a non-fluorescent plastic folder, and scanned for fluorescence using a Molecular Dynamics fluorimager, with the photomultiplier tube set at a voltage of 550 for visualization. The data were analyzed using ImageQuant software with corrections made for local background. A ratio was obtained for each sample by dividing the volume of the band reacted with the anti-active MAPK by the volume of the band with the anti-total MAPK. Theoretically this manipulation should equalize the samples for protein loading, and an increase in this ratio demonstrates an increase in MAPK activation (phosphorylation). For unknown reasons reliable values were obtained for only the p44 MAPK isoform, and not p42 MAPK, possible explanations include difficulty in determining volumes due to sample distortion (e.g. gel frowning), discrepancies in background adjustments, and close proximity of the p44 and p42 bands. From visual examination of the blots it appeared that there was an increase in activated MAPK with the 5 min vasopressin treatment. Analysis of the data using Imagequant (see Table 1 below) demonstrated a trend of increased ratio for the samples treated with vasopressin

for 5 min. However, more work is needed to verify this method for measuring MAPK activation.

**TABLE 1: Ratios of the Band Volumes of Dually Phosphorylated (Active) MAPK to Total MAPK (activated + non-activated) for MCF 7 breast cancer cells treated with 1  $\mu$ M arginine vasopressin for 5 and 15 minutes.**

Sample	P44 MAPK Ratio (5 min)	P44 MAPK ratio (15 min)
Media Control 1	1.72	0.81
Media Control 2	1.70	2.23
Acetic Acid Control 1	2.30	1.93
Acetic Acid Control 2	2.67	2.42
Vasopressin treated 1 (1 $\mu$ M)	2.72	1.67
Vasopressin treated 2 (1 $\mu$ M)	8.25	1.64

#### **D. RT-PCR for vasopressin V1a receptor expression in T47D breast cancer cells**

As discussed in last years progress report we have initiated an RT-PCR approach to examine expression of vasopressin/oxytocin receptor subtypes in cultured breast cancer cells. Using this approach we were able to demonstrate expression of mRNA for the oxytocin receptor, the V<sub>2</sub> vasopressin receptor, the V<sub>1b</sub> vasopressin receptor, and the VACM receptor. Initial attempts at amplifying V<sub>1a</sub> receptor mRNA failed to demonstrate expression of this receptor. However, since that time we have amplified a product of the predicted size of 408 bp from the T47D breast cancer line. This product has not been confirmed by DNA sequencing. The materials and methods used for RT-PCR analyses are as described in last years progress report. These studies address technical objective 3 of the original grant application.

### **(7) CONCLUSIONS**

Previously using the technique of immunohistochemistry and antibodies directed against vasopressin and oxytocin gene-related products we demonstrated that these neuropeptide gene products are commonly expressed in breast cancer (North et al., 1995), but not in benign fibrocystic breast disease (Fay et al., 1997 submitted). These results confirm two published cases of breast cancer patients presenting with the syndrome of inappropriate antidiuretic hormone secretion (Gupta et al., 1986; Howard et al., 1993). These findings suggest that, as in small-cell lung carcinoma, the expression of neuropeptide-related gene- products by cancer cells may be potentially useful diagnostic/therapeutic markers for breast cancer (North et al., 1989; Rosenbaum et al., 1990; North, 1991). This possibility is documented by the fact that using antibodies directed against vasopressin-associated glycopeptide we detect cell surface immunoreactivity in cultured breast cancer cells (see original progress report).

One possible role for the production of small peptide hormones, like vasopressin and oxytocin, by breast cancer cells is that these hormones serve as autocrine/paracrine growth regulatory factors for the cancer cells. This hypothesis seems to be valid since in

vitro (Taylor et al., 1990) and in vivo (Chooi et al., 1994) data indicate that vasopressin stimulates breast cancer growth, and in vitro (Cassoni et al., 1994, 1997) and in vivo (Cassoni et al., 1996) data indicate that oxytocin inhibits breast cancer cell growth. However, the neuropeptide receptors, and the cellular signaling events associated with these hormone-induced growth regulatory effects have not been thoroughly investigated. Work performed in this laboratory (RT-PCR data last progress report) and work published by others (Taylor et al., 1990; Cassoni et al., 1994; Bussolatte et al., 1996; Ito et al., 1996) demonstrate that breast cancer cells express oxytocin receptors. It is of interest that oxytocin receptor activation and growth inhibition of breast cancer cells involves an elevation of cellular cAMP (Cassoni et al., 1997). These results are consistent with our findings of a lack of oxytocin-induced calcium mobilization in the ZR-75 and T47D breast cancer cells. Further research is needed to elucidate the signaling mechanisms involved in oxytocin-induced growth inhibition of breast cancer cells. Such research is of importance since elucidating the mechanisms by which oxytocin causes growth inhibition of breast cancer cells has implications for potential novel therapeutic strategies.

Since vasopressin has been shown to modulate breast cancer cell growth, identifying the receptors involved and the evoked signal transduction pathways is important to understanding how this peptide acts. Research using a cell line derived from a dimethylbenzan(a)anthracene-induced rat mammary tumor demonstrated the presence of  $V_{1a}$  vasopressin receptors (Monaco et al., 1978; Monaco et al., 1980; Guillon et al., 1986; Woods and Monaco, 1988). In addition, Chooi et al. (1994) assumed that the growth promotion of vasopressin they found in an in vivo breast cancer model was due to activation of  $V_{1a}$  receptors. However, RT-PCR data performed in this laboratory indicates that cultured breast cancer cells appear capable of expressing all 4 cloned vasopressin receptors (VACM,  $V_{1a}$ ,  $V_{1b}$ , and  $V_2$ ). Therefore the growth promoting influences of vasopressin in breast cancer cells must be reevaluated. The vasopressin-induced calcium mobilization we found in Zr-75 and T47D breast cancer cells could be due to activation of VACM,  $V_{1a}$ , or  $V_{1b}$  vasopressin receptors, since all these receptors have the potential of increasing levels of intracellular-free calcium. With the cloning of the VACM receptor from cancer cells described in this progress report, we are now able to evaluate the role of the receptor in cancer cell growth by creating breast cancer cell lines which overexpress this receptor. It is of interest that we also find expression of vasopressin  $V_2$  receptor mRNA in breast cancer cells. This receptor could potentially mediate a growth inhibitory effect on breast cancer cell growth since receptor-activation could theoretically raise cellular cAMP levels. and cAMP is growth inhibitory to breast cancer (Tagliaferri et al., 1988). The presence of  $V_2$  receptors could potentially explain the paradoxical growth inhibitory influence of vasopressin that Taylor et al. (1990) found for high doses of vasopressin.

In addition to not knowing the receptors involved in vasopressin-induced growth of breast cancer, the signaling mechanisms are also unknown. One potential signaling pathway for vasopressin to influence cancer cell growth is the mitogen activated protein kinase cascade, since G-protein coupled receptors have been shown to stimulate this pathway through a number of signaling mediators (Robbins et al., 1992; Alblas et al., 1993; Howe and Marshall, 1993; Wintz et al., 1993; Seufferlein et al., 1995). Also, both vasopressin and oxytocin have been shown to activate the MAPK cascade in the

physiological setting (Kribben et al., 1993; Ohmichi et al., 1995; Nohara et al., 1996). Preliminary results obtained in this laboratory indicate that vasopressin-induced stimulation of breast cancer cell growth may be due to activation of the MAPK cascade.

This research has demonstrated the expression of neuropeptide related gene-products for vasopressin and oxytocin in breast cancer, but not benign fibrocystic breast disease. These data set the stage for neuropeptides to serve as growth regulatory factors for breast cancer. Research has indicated that vasopressin and oxytocin may have growth promoting and growth inhibiting influences on breast cancer, respectively. We have demonstrated the expression of mRNAs for the oxytocin receptor, and all known vasopressin receptor subtypes in breast cancer cells. These findings indicate that multiple receptor interactions must be taken into account when deciphering the influence of these peptides on cancer cells. In addition, we have found vasopressin-induced calcium mobilization and preliminary results suggest vasopressin is capable of inducing activation of the MAPK cascade in breast cancer. Such results implicate vasopressin VACM and/or V<sub>1a/1b</sub> receptors in vasopressin growth effects. With our recent cloning of the VACM receptor from cancer cells, we are now able to design experiments where the role of this receptor in cancer cell biology can be evaluated (e.g. receptor overexpression, antisense knockout). The receptors and signal transduction events for the growth regulatory effects of hormones, like vasopressin and oxytocin, remains an understudied area of breast cancer research. Understanding the interactions of hormones with cancer cell growth regulatory mechanisms is essential to identifying potential novel diagnostic and therapeutic strategies for this cancer.

## (8) REFERENCES

- Alblas, J., Van Corven, E.J., Hordikk, P.L., Milligan, G., and Moolenaar, W.H. Gi-mediated activation of the p21ras mitogen-activated protein kinase pathway by  $\alpha$ 2-adrenergic receptors expressed in fibroblasts. *J. Biol. Chem.*, 268:22235-22238, 1993.
- Birnbaumer, M., Seibold, A., Gilbert, S., Ishido, M., Barberis, C., Antaramian, A., Brabet, P., and Rosenthal, W. Molecular cloning of the receptor for human antidiuretic hormone. *Nature*, 357:333-335, 1992.
- Burnatowska-Hledin, M.A., Spielman, W.S., Smith, W.L., Shi, P., Meyer, J.M., and Dewitt, D.L. Expression cloning of an AVP-activated, calcium-mobilizing receptor from rabbit kidney. *Am. J. Physiol.*, 268:F1198-F1210, 1995.
- Bussolati, G., Cassoni, P., Ghisolfi, G., Negro, F., and Sapino, A. Immunolocalization and gene expression of oxytocin receptors in carcinomas and non-neoplastic tissues of the breast. *Am. J. Pathol.*, 148:1895-1903, 1996.
- Byrd, P.J., Stankovic, T., McConville, C.M., Smith, A.D., Cooper, P.R., Taylor, A.M. Identification and analysis of human VACM-1, a cullin gene family member located on chromosome 11q22-23. *Genome Res.*, 7:71-75, 1997.
- Cassoni, P., Sapino, A., Negro, F., and Bussolati, G. Oxytocin inhibits proliferation of human breast cancer cell lines. *Virchows Archiv.*, 425:467-472, 1994.

Cassoni, P., Sapino, A., Papotti, M., Bussolati, G. Oxytocin and oxytocin-analogue F314 inhibit cell proliferation and tumor growth of rat and mouse mammary carcinomas. *Int. J. Cancer*, 66:817-820, 1996.

Cassoni, P., Sapino, A., Fortunati, N., Munaron, L., Chini, B., Bussolati, G. Oxytocin inhibits the proliferation of MDA-MD231 human breast-cancer cells via cyclic adenosine monophosphate and protein kinase A. *Int. J. Cancer*, 72:340-344, 1997.

Cheng, M., Watson, P.H., Paterson, J.A., Seidah, N., Cretien, M., and Shiu, R.P. Pro-protein convertase gene expression in human breast cancer. *Int. J. Cancer*, 71:966-971, 1997.

Chooi, K., Carter, D.A., Biswas, S., Lightman, L., Ho, M., and Murphy, D. Ectopic vasopressin expression in MMTV-*Wnt*-1 transgenic mice modifies mammary tumor differentiation and pathology. *Cancer Res.*, 54:6434-6440, 1994.

Cobb, M.H., and Goldsmith, E.J. How MAP kinases are regulated. *J. Biol. Chem.*, 270:14843-14846, 1995.

Davis, R.J. The mitogen-activated protein kinase transduction pathway. *J. Biol. Chem.*, 268:14553-14556, 1993.

Fay, M.J., Mathew, R.S., Donnelly, E.M., Memoli, V.A., and North, W.G. Immunohistochemical evaluation of vasopressin gene expression in benign breast disease: Preliminary observations. Submitted to *Endocrine Pathology*, 1997.

Guillon, G., Kirk, C.J., and Balestre, M. Characterization of specific V<sub>1a</sub> vasopressin-binding sites on a rat mammary-tumor cell line. *Biochem. J.*, 1986.

Gupta, A., Sasarula, S., and Rao, P.V. The syndrome of inappropriate secretion of antidiuretic hormone in a case of carcinoma of the breast. *J. Assoc. Physicians India*, 34:441-442, 1986.

Hirasawa, A., Shibata, K., Kotosai, K., and Tsujimoto, G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. *Biochem. Biophys. Res. Commun.*, 203:72-79, 1994.

Howard, A.C., Laing, R.W., and Hussain, F.N. Breast carcinoma presenting with inappropriate ADH secretion. *Eur. J. Cancer*, 29A:2339, 1993.

Howe, L.R., and Marshall, C.J. Lysophosphatidic acid stimulates mitogen-activated protein kinase activation via a G-protein-coupled pathway requiring p21ras and p74raf-1. *J. Biol. Chem.*, 268:20717-20720, 1993.

Ito, Y., Kobayashi, T., Kimura, T., Matuura, N., Wakasugi, E., Takeda, T., Shimano, T., Kubota, Y., Nobunaga, T., Makino, Y., Azuma, C., Saji, F., and Monden, M. Investigation of the oxytocin receptor expression in human breast cancer tissue using newly established monoclonal antibodies. *Endocrinol.*, 137:773-779, 1996.

Ivell, R., and Richter, D. The gene for the hypothalamic peptide hormone oxytocin is highly expressed in the bovine corpus luteum: Biosynthesis, structure, and sequence analysis. *EMBO J.*, 3:2351-2354, 1984.

Ivell, R., Brackett, K.H., Fields, M.H., Richter, D. Ovulation triggers oxytocin gene expression in the bovine ovary. *FEBS Lett.*, 190:263-267, 1985.

Keyzer, Y., Auzan, C., Lenne, F., Beldjord, C., Thibonnier, M., Bertanga, X., Clauser, E. Cloning and characterization of the human V3 pituitary vasopressin receptor. *FEBS Letters*, 356:215-220, 1994.

- Kimura, T., Tanizawa, O., Mori, K., Brownstein, M.J., and Okayama, H. Structure and expression of a human oxytocin receptor. *Nature*, 356:526-529, 1992.
- Kribben, A., Wieder, E.D., Li, X., van Putten, V., Granot, Y., Schrier, R.W., Nemenoff, R.A. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. *Am. J. Physiol.*, 256:c939-c945, 1993.
- L'Allemain, G. Deciphering the MAP kinase pathway. *Progress in Growth Factor Res.*, 5:291-334, 1994.
- Lopez, I., Iasaca, M., Crespo, P., Giuseppe Pellici P., Silvio Gutkind, J., and Wetzker, R. Linkage of G-protein-coupled receptors to the MAPK signaling pathway through PI 3-Kinase  $\gamma$ . *Science*, 275:394-397, 1997.
- Milligan, G. Mechanisms of multifunctional signaling by G protein-linked receptors. *Trends in Pharmacological Sciences*, 14:239-244, 1993.
- Monaco, M.E., Lippman, M.E., Knazek, R., and Kidwell, W.R. Vasopressin stimulation of acetate incorporation into lipids in a dimethylbenz(a)anthracene-induced rat mammary tumor cell line. *Cancer Res.*, 38:4101-4104, 1978.
- Monaco, M.E., Kidwell, W.R., and Lippman, M.E. Neurohypophysial-hormone-responsive cell line derived from a dimethylbenzanthracene-induced rat mammary tumor. *Biochem. J.*, 188:437-441, 1980.
- Nicholson, H.D., Swann, R.W., Burford, G.D., Wathes, D.C., Porter, D.C., Pickering, B.T. Identification of oxytocin and vasopressin in the testis and adrenal tissue. *Regul. Peptides* 8:141-146, 1984.
- Nohara A, Ohmichi M, Koike K, Masumoto N, Kobayashi M, Akahane M, Ikegami H, Hirota K, Miyake A, Murata Y. The role of mitogen-activated protein kinase in oxytocin-induced contraction of uterine smooth muscle in pregnant rat. *Biochem. Biophys. Res. Commun.* 229(3):938-944, 1996.
- North, W.G., 1987, Biosynthesis of vasopressin and neurophysins, in: *Vasopressin*. ed. D.M. Gash and G.J. Boer, pp. 175-209, Plenum Publishing Corp.
- North, W.G., Hirsch, V., Lisboa, R., Schulz, J., and Cooper, B., Imaging of small cell carcinoma using  $^{131}\text{I}$ -labeled antibodies to vasopressin associated human neurophysin (VP-HNP). *Nuclear Med. Commun.*, 10:643-651, 1989.
- North, W.G. Neuropeptide production by small cell carcinoma: vasopressin and oxytocin as plasma markers of disease. *J. Clin. Endocrinol. Metab.*, 73:1316-1320, 1991.
- North, W.G., and Yu, X. Vasopressin mRNA and neurophysin-related cell-surface antigen (NRSA) in small cell carcinoma. *Peptides*, 14:303-307, 1993.
- North, W.G., Pai, S., Friedmann, A., Yu, X., Fay, M., and Memoli, V. Vasopressin gene related products are markers of human breast cancer. *Breast Cancer Research and Treatment*, 34:229-235, 1995.
- Nussey, S.S., Ang, V.T.Y., Jenkins, J.S., Chowdrey, H.S., Bissett, G.W. Brattleboro rat adrenal contains vasopressin. *Nature*, 310:64-66, 1984.
- Ohmichi, M., Koike, K., Nohara, A., Kanda, Y., Sakamoto, Y., Zhang, Z.X., Hiroto, K., and Miyake, A. Oxytocin stimulates mitogen-activated protein kinase activity in cultured human puerperal uterine myometrial cells. *Endocrinol.*, 135:2082-2087, 1995.
- Robbins, D.J., Cheng, M., Zhen, E., Vanderbilt, C.A., Feig, L.A., and Cobb, M.H. Evidence for a Ras-dependent extracellular signal-regulated kinase (ERK) cascade. *Proc. Natl. Acad. Sci. USA*, 89:6924-6928, 1992.

Rosenbaum, L.C., Neuwelt, E.A., Van Tol, H.H.N., Loh, Y.P., Verbalis, J.G., Hellstrom, I., Hellstrom, K.E., and Nilaver, G. Expression of neurophysin-related precursor in cell membranes of small-cell lung carcinoma. *Proc. Natl. Acad. Sci. USA*, 87:9928-9932, 1990.

Sausville, E., Carney, D., and Battey J. The human vasopressin gene is linked to the oxytocin gene and is selectively expressed in a cultured lung cancer cell line. *J. Biol. Chem.* 260:10236-10241, 1985.

Schwams, D., Kruij, T.A., Koll, R. Oxytocin determination in steroid producing tissues and in vitro production in ovarian follicles. *Acta Endocrinol.*, 109:530-536, 1985.

Seufferlein, T., Withers, D.J., Broad, S., Herget, T., Walh, J.H., and Rozengurt, E. The human CCKB/gastrin receptor transfected into rat 1 fibroblasts mediates activation of MAP kinase, p74raf-1 kinase, and mitogenesis. *Cell growth and differentiation*, 6:383-393, 1995.

Sorensen, J.B., Andersen, M.K., and Hansen H.H. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. *J. Internal Med.*, 238:97-110, 1995.

Stankovic, T., Byrd, P.J., Cooper, P.R., McConville, C.M., Munroe, D.J., Riley, J.H., Watts, G.D., Ambrose, H., McGuire, G., Smith, A.D., Sutcliffe, A., Mills, T., Taylor, A.M. Construction of a transcription map around the gene for ataxia telangiectasia: identification of at least four novel genes. *Genomics*, 40:267-276, 1997.

Tagliaferri, P., Katsaros, D., Clair, T., Ally, S., Tortora, G., Neckers, L., Rubalcava, B., Parandoosh, Z., Chang, Y., Revankar, G.R., Crabtree, G.W., Robins, R.K., Cho-Chung, Y.S. Synergistic inhibition of growth of breast and colon human cancer cell lines by site selective cyclic AMP analogues. *Cancer Res.*, 48:1642-1650, 1988.

Taylor, A.H., Ang, V.T.Y., Jenkins, J.S., Silverlight, J.J., Coombes, R.C., and Laqmani, Y.A. Interaction of vasopressin and oxytocin with human breast carcinoma cells. *Cancer Res.*, 50:7882-7886, 1990.

Thibonnier, M., Auzan, C., Madhum, Z., Wilkins, P., Berti-Mattera, L., and Cluaser, E. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V<sub>1a</sub> vasopressin receptor. *J. Biol. Chem.*, 269:3304-3310, 1994.

Wathes, D.C., and Swann, R.W. Is oxytocin an ovarian hormone? *Nature*, 297:225-227, 1982.

Wathes, D.C. Possible actions of gonadal oxytocin and vasopressin. *J. Reprod. Fertil.*, 71:315-345, 1984.

Wintz, S., Russell, M., Qian, N., Gardner, A., Dwyer, L., and Johnson, G.L. Involvement of ras and raf in the Gi-coupled acetylcholine muscarinic m2 receptor activation of mitogen-activated protein (MAP) kinase kinase and MAP kinase. *J. Biol. Chem.*, 268:19196-19199, 1993.

Woods, D.J., and Monaco, M.E. Characterization of the vasopressin receptor on WRK-1 cells. *Mol. Endocrinol.*, 2:350-354, 1988.



## **(9) APPENDICES**

The following items are located in the Appendices:

1. **K.A. Longo, W.G. North, J. Du, and M.J. Fay.** Evidence for the expression of a novel vasopressin-activated calcium mobilizing receptor (HVACM) in human breast cancer and lung cancer. 1997 World Congress of Neurohypophysial Hormones (Montreal, Canada) August 8 - 12, 1997.
2. **Fay, M., Du, J., Longo, K., and North, W.** The role of vasopressin and oxytocin hormones in breast cancer. The Department of Defense Era of Hope Breast Cancer Research Program Meeting (Washington, D.C.) October 31 - November 4, 1997.
3. A copy of our genbank submission for homo sapiens vasopressin-activated calcium mobilizing putative receptor protein (VACM-1) mRNA and protein, genbank accession number AF017061.

August 8 - 12, 1997

Mail to:  
 WCNH Secretariat  
 Conference Office, McGill University  
 550 Sherbrooke Street West, West Tower, Suite 490  
 Montreal, Qc, Canada H3A 1B9

Telephone: (514) 398-3770  
 Fax: (514) 398-4854  
 Email: WCNH@ums1.lan.mcgill.ca  
 Website: <http://www.mcgill.ca/mco/wcnh>  
 Deadline for Abstract submissions: March 14, 1997

Complete the following if no address appears in the box. If there are errors, fill in correct information.

☐ Dr. ☒ Mr. ☐ Mrs. ☐ Ms.

First name Kenneth

Family name Longo

Institution Dartmouth Medical School

Address 1 Medical Center Drive

Dr. Michael Fay  
 Dartmouth Inst.  
 Physiology Dept.  
 Lebanon, NH  
 U.S.A.  
 03756

2378

City Lebanon Province / State NH Country USA Postal code / Zip 03756

Telephone (603) 650-7736 Fax: (603) 650-6130 Email [kenneth.longo@dartmouth.edu](mailto:kenneth.longo@dartmouth.edu)

Abstract title Evidence for the expression of a novel vasopressin-activated calcium mobilizing receptor (HVACM) in human breast cancer and lung cancer cell lines

Authors including presenter (Please underline presenter's name)

Institutions

1 Kenneth A. Longo

1 Dartmouth Medical School

2 William G. North, Ph.D.

2 Dartmouth Medical school

3 Jinlin Du, M.D.

3 dartmouth Medical School

4 Michael J. Fay, Ph.D.

4 Dartmouth Medical School

Please submit additional authors on a separate sheet of paper

Please type text of abstract ONLY (not title) within this frame

The purpose of this study was to determine if a human homologue of the rabbit vasopressin-activated calcium mobilizing (VACM-1) receptor is expressed in human cancer cells. Vasopressin (AVP) may be involved in human breast cancer and lung cancer pathophysiology, as an autocrine/paracrine factor. AVP can act through four classes of receptors: V2, V1a, V1b, and the recently cloned VACM-1, a structurally unique member of this group that contains a single transmembrane domain. (Recently, a highly homologous cDNA, termed HVACM, was cloned from human placental mRNA.) AVP induced an increase in intracellular free calcium in the breast cancer cell lines MCF-7, T47-D, and ZR-75, and in the lung cancer cell line NCI H-146. Total RNA from these cell lines and normal human tissues (kidney and lung), was used for reverse transcription polymerase chain reaction (RT-PCR) and Northern blot analysis. RT-PCR, using two primer sets designed against the rabbit VACM-1 sequence, amplified bands of the predicted sizes of 674 bp and 193 bp in all cell lines and tissues tested. Direct sequencing of PCR products obtained from H-146 revealed a high degree of identity to the rabbit VACM-1 cDNA (90%) and the human HVACM cDNA (99.5%). Northern blot analysis revealed three distinct bands (3.5, 5 and 6.5 kilobases) in the cancer cell lines. In summary, we have demonstrated the presence of mRNA for a novel AVP receptor in human cancer cell lines and normal human tissues.

## **THE ROLE OF VASOPRESSIN AND OXYTOCIN HORMONES IN BREAST CANCER**

**Michael Fay, Ph.D., Jinlin Du, MD.,  
Kenneth Longo, and William North, Ph.D.**

Department of Physiology, Dartmouth Medical School,  
1 Medical Center Drive, 752E Borwell, Lebanon, NH 03756.

Research performed in this laboratory shows that breast cancer cells produce small peptide hormones like vasopressin and oxytocin. Other laboratories have demonstrated that vasopressin and oxytocin modulate breast cancer cell growth. How these peptides influence breast cancer cell growth and the cell surface hormone receptors involved are unknown. Using the technique of reverse transcription polymerase chain reaction (RT-PCR) we were able to demonstrate mRNA(s) for the oxytocin receptor, the vasopressin-activated calcium mobilizing receptor (VACM), the V1a vasopressin receptor, the V1b vasopressin receptor, and the V2 vasopressin receptor in a number of breast cancer cell lines. Collectively these results indicate that breast cancer cells produce neuropeptide receptors through which vasopressin and oxytocin might act to influence breast cancer cell growth. To examine cellular changes associated with receptor activation and cell growth, we evaluated neuropeptide-induced changes in intracellular free calcium and activation of the mitogen-activated protein kinase cascade. Results using two cultured breast cancer cell lines shows that vasopressin, but not oxytocin, was capable of increasing intracellular free calcium. Data using the MCF-7 breast cancer cell line suggest that one manner through which vasopressin might stimulate breast cancer cell growth is through activation of the MAP kinase cascade. Identifying hormones involved in breast cancer cell growth, the hormone receptors through which these peptides act, and the cellular changes associated with receptor activation is crucial to identifying novel strategies for the treatment of breast cancer.

Using the technique of RT-PCR evidence was obtained for the expression of mRNA(s) for a number of vasopressin and oxytocin receptor subtypes in cultured breast cancer cell lines. Using two primer pairs based on the sequence of the VACM receptor, PCR products of the predicted sizes of 674 bp and 193 bp were amplified from MCF-7, T47D, and ZR-75 breast cancer cell lines. Using a primer pair based on the oxytocin receptor, a PCR product of the predicted size of 391 bp was amplified from BT549, MCF-7, MDA-MB-231, T47D, and ZR-75 breast cancer cell lines. From the ZR-75, BT549, and MCF-7 cell lines a PCR product of the predicted size of 862 bp was amplified using primers for the V2 vasopressin receptor. In addition, using the V2 receptor primers, a PCR product which is approximately 100 bp larger than expected was amplified from these three cell lines. It is believed that this PCR product represents an incompletely spliced mRNA species containing the second intron. Using Primer pairs that amplify a 239 bp PCR product for the V1b vasopressin receptor, a product of the predicted size was amplified from the MCF7 breast cancer cell line. Preliminary PCR results using a primer pair based on the V1a vasopressin receptor indicate that a PCR product of the predicted size of 408 bp was amplified from the T47D breast cancer cell line. The identity of the VACM and V1b PCR products has been verified by direct DNA sequencing of the PCR products. Northern blot analysis for VACM using RNA from the ZR-75, MCF-7, and T47D cell lines indicates RNA species of ~ 3.5, 5, and 6.5 Kb. Using indo-1 AM loaded ZR-75 and T47D breast cancer cells neuropeptide induced changes in intracellular free calcium was monitored using flow cytometric analysis. Vasopressin (0, 10 nM, 100 nM, and 1,000 nM) was administered after approximately 20 seconds of baseline. In both cell lines vasopressin at the 100 nM and 1,000 nM doses induced a rise in intracellular-free calcium as indicated by an increase in the 405nm/485nm ratio. At all the doses studied oxytocin (10 nM, 100 nM, 1,000 nM) did not cause a noticeable rise in intracellular-free calcium in the ZR-75 and T47D cell lines. Treatment of MCF-7 breast cancer cells with 100 nM and 1,000 nM vasopressin resulted in a dose-dependent increase in tyrosine phosphorylated MAP kinase as determined by Western blot analysis.

Both in vivo and in vitro results indicate that neuropeptides like vasopressin can serve as growth modulating agents for breast cancer. Research performed in this laboratory indicates that neuropeptides, like vasopressin and oxytocin, are produced by breast cancer cells. Collectively these results suggest that neuropeptide hormones may serve as autocrine/paracrine factors for breast cancer. The results obtained in these studies provide further support for a role of vasopressin and oxytocin as paracrine/autocrine factors for breast cancer since mRNA(s) for a number of receptors for these hormones are expressed in cultured breast cancer cells. Vasopressin treatment causes a rise in intracellular free calcium in two cultured breast cancer cell lines, suggesting that the hormone might be activating VACM, V1a, or V1b receptor subtypes. Experimental results obtained with the MCF-7 breast cancer cell line suggest that the influence of vasopressin on breast cancer cell growth observed in vivo and in vitro may be due to activation of the MAP kinase cascade. These results further support a role for neuropeptide hormones like vasopressin and oxytocin in breast cancer pathophysiology. Identifying hormones involved in breast cancer cell growth, the hormone receptors through which these peptides act, and the cellular changes associated with receptor activation is crucial to identifying novel strategies for the treatment of breast cancer.

Michael J. Fay, Ph.D.

Dartmouth Medical School, Department of Physiology,  
1 Medical Center Drive, 752E Borwell, Lebanon, NH 03756.

References (papers and abstracts)

1. North WG, Pai S, Friedmann A, Yu X, Fay M, and Memoli V. Vasopressin gene related products are markers of human breast cancer. *Breast Cancer Research and Treatment* 1995;34:229-235.
2. Gallagher JD, Fay MJ, North WG, and McCann FV. Ionic signals in T47D human breast cancer cells. *Cellular Signaling* 1996;8(4):279-284.
3. Fay MJ, Mathew RS, Donnelly EM, Memoli VA, and North WG. Immunohistochemical evaluation of vasopressin gene expression in fibrocystic breast disease. *Endocrine Pathology* (submitted), paper in press.
4. Fay MJ, Yu X, Memoli V, and North WG. Expression of the vasopressin gene by human breast cancer. *Mol Biol Cell* 1994; 5:2730 (abstract).
5. Fay MJ, Yu X, Memoli V, and North WG. Expression of the vasopressin gene by human breast cancer. *Gordon Conference, Mammary Gland Biology* (Colby Sawyer College, New London, NH), June 18-23, 1995 (abstract).
6. Longo KA, Fay MJ, Du J, and North WG. Evidence for the expression of a novel vasopressin-activated calcium mobilizing receptor (VACM-1) in human breast cancer and lung cancer. *Mol Biol Cell* 1996;7:3761 (abstract).
7. North WG, Fay MJ, Du J. Vasopressin and breast cancer, gene expression and trafficking. *Summer neuropeptide conference* (Key West, FL), June 21-26, 1997 (abstract).
8. Longo KA, North WG, Du J, Fay MJ. Evidence for the expression of a novel vasopressin-activated calcium mobilizing receptor (HVACM) in human breast cancer and lung cancer cell lines. *1997 World congress of neurohypophysial hormones* (Montreal, Canada) August 8-12, 1997 (abstract).

This work was supported by the U.S. Army Medical Research and Material Command under DAMD 17-94-j-4131.

## **THE ROLE OF VASOPRESSIN AND OXYTOCIN HORMONES IN BREAST CANCER**

**Michael Fay, Ph.D., Jinlin Du, MD, Kenneth Longo,  
and William North, Ph.D.**

Department of Physiology, Dartmouth Medical School,  
1 Medical Center Drive, 752E Borwell, Lebanon, NH 03756.

This laboratory has demonstrated that fixed breast cancer biopsy specimens exhibit positive immunoreactivity for vasopressin and oxytocin gene-related products using the technique of immunohistochemistry and antibodies directed against different regions of the vasopressin and oxytocin prohormones. In addition, both in vitro and in vivo research indicate that neuropeptides, like vasopressin and oxytocin, modulate breast cancer cell growth. Taken together these results suggest that vasopressin and oxytocin may serve as autocrine and/or paracrine growth modulators for breast cancer cells. However, the receptors and signal transduction pathways through which vasopressin and oxytocin act to influence breast cancer cell growth remain unknown. The purpose of this research is to determine if breast cancer cells express vasopressin and oxytocin receptors, and to evaluate vasopressin- and oxytocin-induced signal transduction in breast cancer cells.

To evaluate which vasopressin and oxytocin receptor subtypes are expressed by breast cancer cells the technique of reverse-transcription polymerase chain reaction (RT-PCR) was used with primer pairs specific for the oxytocin receptor, the V1a vasopressin receptor, the V1b vasopressin receptor, the V2 vasopressin receptor, and the vasopressin-activated calcium mobilizing receptor (VACM). The VACM and V1b receptor PCR products were confirmed by direct DNA sequencing. To study vasopressin and oxytocin induced changes in intracellular-free calcium, breast cancer cells were loaded with indo-1 AM, and neuropeptide-induced changes in intracellular free calcium monitored over a four minute period using a Becton Dickinson Facstar Plus flow cytometer [excitation 356 nm, emissions 405 nm (calcium bound indo), and 485 nm (free indo)]. To determine if vasopressin causes activation of the mitogen activated protein kinase cascade (MAP kinase), MCF-7 breast cancer cells were stimulated with vasopressin, and activated (phosphorylated) MAP Kinase evaluated by western blot analysis.

**Keywords: Breast Cancer Cells, Vasopressin and Oxytocin, Vasopressin and Oxytocin Receptors, Signal Transduction.**

This work was supported by the U.S. Army Medical Research and Material Command under DAMD 17-94-j-4131.

LOCUS AF017061 2461 bp mRNA PRI 16-SEP-1997  
 DEFINITION Homo sapiens vasopressin-activated calcium mobilizing putative  
 receptor protein (VACM-1) mRNA, complete cds.  
 ACCESSION AF017061  
 NID g2394273  
 KEYWORDS .  
 SOURCE human.  
 ORGANISM Homo sapiens  
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;  
 Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 2461)  
 AUTHORS Longo,K.A., North,W.G., Du,J. and Fay,M.J.  
 TITLE Direct Submission  
 JOURNAL Submitted (02-AUG-1997) Department of Physiology, Dartmouth Medical  
 School, 1 Medical Center Drive, Lebanon, NH 03755, USA  
 FEATURES  
 source  
 1..2461  
 /organism="Homo sapiens"  
 /cell\_line="NCI-H146"  
 1..2461  
 /gene="VACM-1"  
 1..2346  
 /gene="VACM-1"  
 /note="HSVACM1"  
 /codon\_start=1  
 /product="vasopressin-activated calcium mobilizing  
 putative receptor protein"  
 /db\_xref="PID:g2394274"  
 /translation="MATSNLLKDKGFLQFGDKWDFMRPIVLKLLRRDFVTKRQWFDLF  
 SDVHAFCFWDDKGPAKIHQALKEDFILEFIKQAQARVLSHQDDTALLKAYIVEWRKFF  
 TQCDILPKPFCQLEITLMGKQGSNKKSNEDESIVRKMLMLDTWNESIFSNIKRLQDSA

MKLVHAERLGEAFDSQLVIGVRESYVNLCSNPEDKLQIYRDNFEKAYLDSTERFYRTQ  
 APSYLQQNGVQNYMKYADAKLKEEKRALRYLETRRECNSVEALMECCVNALVTSEKE  
 TILAECQGMIKRNETEKHLMFSLMDKVPNGIEPMLKDLEEHISAGLADMVAAAEI  
 TTDSEKYVEQLLTLFNRFSKLVKEAFQDDPRFLTARDKAYKAVVNDATIFKLELPLKQ  
 KGVGLKTQPESKPELLANYCDMLLRKTPLSKKLTSEEIEAKLKEVLLVLKYVQNKDV  
 FMRYHKAHLTRRLILDISADSEIEENMVLEWREVGMADYVVKLARMEFQDIKVSIEDLN  
 QAFKEMHKNNKLALPADSVNIKILNAGAWSRSSEKVFVSLPTELEDLIPVEEFYKKN  
 HSGRKLHWHHLSNGIITFKNEVGQYDLEVTTFQLAVLFAWNQRPREKISFENLKLAT  
 ELPDAELRRTLWSLVAFPKLRQVLLYEPQVNSPKDFTEGTLFSVNQEFSLIKNAKVQ  
 KRGKINLIGRLQLTTERMREENEGIVQLRILRTQEAIIQIMKMRKKISNAQLQTELV  
 EILKNMFLPQKKMIKEQIEWLIEHKYIRDESINTFIYMA"

3'UTR

2347..>2461

/gene="VACM-1"

BASE COUNT 877 a 378 c 512 g 694 t

ORIGIN

1 atggcgacgt ctaatctgtt aaaggataaa ggttttcttc agtttgaga caaatgggat  
 61 tttatgcgcc cgattgtttt gaagctttta cgccgggatt ttgttataaa acggcagtg  
 121 tttgatctgt tttcggatgt gcatgcattc tgtttttggg atgataaaagg ccagcaaaa  
 181 attcatcagg ctttaaagga agattttatt cttgagttta ttaagcaagc acaggcacga  
 241 gtactgagcc atcaagatga tacggctttg ctaaaagcat atattgttg atggcgaaag  
 301 ttctttacac aatgtgatat tttaacaaa cctttttgtc aactagagat tactttaatg  
 361 ggtaaacagg gcagcaataa aaaatcaaat gtggaagaca gtattgttcg aaagcttatg  
 421 cttgatacat ggaatgagtc aatcttttca aacataaaaa acagactcca agatagtga  
 481 atgaagctgg tacatgctga gagattggga gaagcttttg attctcagct ggttatgga  
 541 gtaagagaaat cctatgttaa cctttgttct aatcctgagg ataaacttca aatttatagg  
 601 gacaattttg agaaggcata cttggattca acagagagat ttatagaac acaagcacc  
 661 tcgtatttac aacaaaatgg tgtacagaat tatatgaaat atgcagatgc taaattaaaa  
 721 gaagaagaaa aacgagcact acgttattta gaaacaagac gagaatgtaa ctccgttgaa  
 781 gactcatgg aatgctgtgt aaatgccctg gtgacatcat ttaaagagac tatcttagct  
 841 gagtgccaaag gcatgatcaa gagaaatgaa actgaaaaat tacatttaat gttttcattg  
 901 atggacaaag ttcctaattg tatagagcca atgttgaaag acttgagga acatatcatt  
 961 agtgctggcc tggcagatat ggtagcagct gctgaaacta ttactactga ctctgagaaa  
 1021 tacgttgagc agttacttac actattaat agatttagta aactcgtcaa agaagctttt



1081 caagatgac cacgatttct tactgcaaga gataaggcgt ataaagcagt tgtaaatgat  
1141 gctaccatat ttaaaacttga attacctttg aagcagaagg gggtaggatt aaaaactcag  
1201 cctgaatcaa aatgccctga gctgcttgcc ctctgaagag attgaagcaa agcttaaaga agtgctcttg  
1261 ccattaagca aaaaactaac ctctgaagag caaagatgtt ttatgaggt atcataaagc tcatttgaca  
1321 gtacttaagt atgtacagaa ttggtatgcc agcggattat gttaacaagc ttgctagaat gtttcaggac  
1381 cgacgtctta tattagacat ctctgccgat agtgaattg aagaaaaacat ggtagagtgg  
1441 ctaagagaag ttggtatgcc agcggattat gttaacaagc ttgctagaat gtttcaggac  
1501 ataaaagtat ctgaagattt gaaccaagct ttaaggaaa tgcacaaaaa taataaatg  
1561 gcattaccag ctgattcagt taatataaaa attctgaatg ctggcgccctg gtcaagaagt  
1621 tctgagaaaag tctttgtctc acttcctact gaactggagg acttgatacc ggaagtagaa  
1681 gaattctaca aaaaaaatca tagtggtaga aaattacatt ggcatcatct catgtcaaat  
1741 ggaattataa catttaagaa tgaagttggt cccagagaga aaatcagctt caggtttcag  
1801 ctgcgtgtat tgtttgcatt gaaccaaaaga cctagaggga ctttatggct tttagtagct  
1861 aagcttgcaa ctgaaactccc agttttgttg ctcaagtgaac caggagttca gtttaataaa aaatgcaaa  
1921 ttcccaaaac tcaaacggca agttttgttg tatgaaacct aagtcactc acccaaaagac  
1981 ttacagaag gtaccctctt ctcaagtgaac caggagttca gtttaataaa aaatgcaaa  
2041 gttcagaaaa ggggtaaaat caacttgatt ggacgtttgc agtcactac agaaaggatg  
2101 agagaagaag agaatgaagg aatagttcaa ctacgaatac taagaaccca ggaagctatc  
2161 atacaaaataa tgaaaatgag aaagaaaatt agtaatgctc agctgcagac tgaattagta  
2221 gaaattttga aaaacatggt ctgcccacaa aagaaaaatga taaaagagca aatagagtgg  
2281 ctaatagagc acaaatatcat cagaagagat gaatctgata tcaacacttt catatatatg  
2341 gcataaatatt gaatatcatg gacaatatatt agaaccacaa ttttgagtg cttgggcaga  
2401 aagttgtaaa gtttgtgctg gagaaagggt tatttgact ttgattacat aaatattaat  
2461 a

//